Screener / SEC EDGAR /CIK 0001070494 /10-K filed Feb 26, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Acadia Pharmaceuticals Inc ACAD

Compare with peers Embed
Earnings releases

Latest results release: Nov 4, 2026

8-K item 2.02, exhibit 99

What ACAD's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 4, 2026 · EX-99.1

Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results

Open on SEC

Exhibit 99.1 Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results

- Third quarter GAAP total revenues of $342 million, up 22% year-over-year as compared to non-GAAP adjusted total revenues

- Third quarter DAYBUE®GAAP net sales of $140 million, up 39% year-over-year driven by strong uptake of DAYBUE STIX

- Third quarter NUPLAZID®GAAP net sales of $202 million, up 12% year-over-year on a non-GAAP adjusted basis

- Raises 2026 DAYBUE net sales guidance to $505–$520 million; narrows NUPLAZID range and total revenue range

- Additional data from Phase 3-enabling RADIANT Phase 2 Study to be presented at the Clinical Trials on Alzheimer’s Disease conference on November 17 SAN DIEGO, CA, November 4, 2026– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third quarter ended September 30, 2026.

“Acadia delivered a strong third quarter, with total revenues of $342 million and continued commercial momentum across DAYBUE and NUPLAZID,” said Catherine Owen Adams, Chief Executive Officer of Acadia. “In the U.S., DAYBUE delivered another strong quarter, supported by meaningful uptake of DAYBUE STIX. In Europe, we are excited to build momentum following our recent launch of DAYBU in Germany. NUPLAZID also performed well, driven by underlying demand and the continued expansion of our commercial reach. Together, these growing franchises provide the commercial and financial foundation to advance clinical programs with the potential to become Acadia’s next meaningful growth opportunities. In Alzheimer’s disease psychosis, we are continuing Phase 3 development of remlifanserin based on Phase 2 results. As we look ahead to 2027, we anticipate two Phase 2 readouts: ACP-211 in major depressive disorder, and remlifanserin in Lewy body dementia psychosis, for which we are providing timing guidance for the first time. We look forward to sharing these updates as we continue to advance the next wave of our pipeline.”

Announced Phase 3-enabling topline results from the Phase 2 RADIANT study of remlifanserin in Alzheimer’s disease psychosis, with consistent efficacy trends at the 60 mg dose across all four psychosis scales that were assessed for the full study population and a favorable safety and tolerability profile supporting continued and optimized Phase 3 development. Additional data will be presented at the Clinical Trials on Alzheimer’s Disease conference on November 17, 2026, in Boston.

Two Phase 2 readouts anticipated in 2027: ACP-211 in major depressive disorder (MDD) in the second half and, for the first time, guidance for remlifanserin in Lewy body dementia Psychosis (LBDP) in the fourth quarter.

Received FDA Fast Track designation for remlifanserin for the treatment of Lewy body dementia psychosis, recognizing the significant unmet need for new treatment options.

Received allowance of a new U.S. patent covering weight-banded dosing of trofinetide, extending U.S. patent protections for DAYBUE and DAYBUE STIX by nearly five years, through March 2041.

Received European Commission approval for DAYBU ® (trofinetide) as the first and only treatment for the neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older in the European Union in August 2026 and launched DAYBU in Germany in early October 2026 with patients already receiving commercial product.

Completed the Phase 3 study of trofinetide in Rett syndrome in Japan, with results consistent with the LAVENDER Phase 3 study and supportive of a planned regulatory filing; Acadia continues to pursue a distribution partner in preparation for regulatory filing in 2027 and a potential launch in 2028, subject to regulatory approval.

GAAP total revenues, consisting of net product sales from NUPLAZID and DAYBUE, were $342 million in the third quarter of 2026, up 23% as compared to GAAP total revenues of $279 million in the third quarter of 2025, and up 22% as compared to non-GAAP adjusted total revenues of $281 million in the third quarter of 2025.

GAAP net product sales of NUPLAZID were $202 million in the third quarter of 2026, up 14% as compared to GAAP net product sales of $178 million in the third quarter of 2025, and up 12% as compared to non-GAAP adjusted net product sales of $180 million in the third quarter of 2025.

Net product sales of DAYBUE were $140 million in the third quarter of 2026, an increase of 39% as compared to $101 million in the third quarter of 2025.

A reconciliation of NUPLAZID non-GAAP adjusted net product sales and non-GAAP adjusted total revenues is provided in Table 1. A description of these adjustments is included under ‘Non-GAAP Financial Measures.’

Research and development expenses in the third quarter of 2026 were $76 million, as compared to $88 million for the same period of 2025.

Selling, general and administrative expenses in the third quarter of 2026 were $159 million, as compared to $133 million for the same period of 2025.

For the third quarter of 2026, Acadia reported net income of $54 million, or $0.31 per diluted share, as compared to net income of $72 million, or $0.42 per diluted share, for the same period of 2025.

At September 30, 2026, Acadia’s cash, cash equivalents, and investment securities totaled $976 million, as compared to $820 million at December 31, 2025.

Total revenues revised to a range of $1.265 to $1.295 billion, compared with a previous range of $1.24 to $1.30 billion.

NUPLAZID net product sales narrowed to a range of $760 to $775 million, compared with the previous guidance range of $760 to $790 million.

DAYBUE (including all forms of trofinetide) global net product sales in the range of $505 to $520 million, up from the previous range of $480 to $510 million.

R&D expense in the range of $325 to $340 million, down from the previous range of $355 to $380 million.

SG&A expense in the range of $665 to $685 million, compared with the previous guidance range of $660 to $700 million.

Acadia will host a conference call to discuss the third quarter 2026 results today, Wednesday, November 4, 2026 at 1:30 p.m. PT/4:30 p.m. ET. The conference call may be accessed by registering for the callhere. Once registered, participants will receive an email with the dial-in number and unique PIN to use for accessing the call.

Pimavanserin is a selective serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors. These receptors are thought to play an important role in neuropsychiatric disorders. In vitro, pimavanserin demonstrated no appreciable binding affinity for dopamine (including D2), histamine, muscarinic, or adrenergic receptors. Pimavanserin was approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis by the U.S. Food and Drug Administration in April 2016 under the trade name NUPLAZID.

Trofinetide is a synthetic version of a naturally occurring molecule known as the tripeptide glycine-proline-glutamate (GPE). The mechanism by which trofinetide exerts therapeutic effects in patients with Rett syndrome is unknown. Trofinetide was first approved for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older by the U.S. Food and Drug Administration in March 2023 under the trade name DAYBUE. Trofinetide is approved for use under the name DAYBUE®and DAYBUE®STIX in the United States and under the name DAYBUE®in Canada and DAYBU®in the European Union. References to DAYBUE net product sales include global net product sales of all commercially available forms of trofinetide, including those referenced above.

Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse

pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we’re here to be their difference. For more information, visit us at acadia.com and follow us onLinkedInandX.

This press release contains the following financial measures that do not comply with U.S. generally accepted accounting principles (GAAP): non-GAAP adjusted net product sales for NUPLAZID for the third quarter of 2025 and non-GAAP adjusted total revenues for the third quarter of 2025. In preparing these non-GAAP financial results, the Company includes adjustments made to reflect the impact of a change in estimate related to NUPLAZID IRA rebate accruals. Please refer to our press release dated February 25, 2026, for additional details. These non- GAAP financial measures complement GAAP results and are used by management to analyze financial performance and evaluate period-to-period changes. Management believes these non-GAAP financial measures are useful to investors and other users of the Company’s financial statements to facilitate period-to-period comparability. These non-GAAP financial measures are not meant to be considered as a substitute for comparable GAAP measures; should be read in conjunction with the Company’s consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are unlikely to be comparable with non-GAAP disclosures released by other companies.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact and can be identified by terms such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “potential,” “guidance,” “continue” and similar expressions (including the negative thereof) intended to identify forward-looking statements. Forward-looking statements contained in this press release, include, but are not limited to, statements about: (i) our business strategy, objectives and opportunities, including support for and innovations in our pipeline assets and business development opportunities, sales growth for DAYBUE [products] and uptake of DAYBUE STIX and DAYBU in the European Union and the potential for enhanced shareholder value; (ii) the momentum and expectations for NUPLAZID’s commercial reach, (iii) the strength and loss of exclusivity date of our trofinetide patent protection; (iv) plans for, including timing, development and progress of commercialization, clinical and regulatory milestones for, our products and our product candidates, including trofinetide in Japan, remlifanserin in ADP and LBDP, and ACP-211 in MDD; (v) benefits to be derived from and efficacy of our products, including the potential advantages of our products; (vi) our expectations to advance our clinical programs and their potential to become meaningful growth opportunities, including our belief that the results from the Phase 2 RADIANT study will enable the Phase 3 study of remlifanserin in Alzheimer’s disease psychosis; (vii) our plans to pursue distribution partnerships for trofinetide in Rett syndrome; and (viii) our estimates regarding our future financial performance, profitability, capital requirements or expenses, including our full year 2026 financial guidance, revenue opportunities and anticipated net product sales by the end of 2028. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. Such risks, uncertainties and other factors include, but are not limited to: our dependency on the continued successful commercialization of our products and our ability to maintain or increase sales of our products; the success of our plans to continue commercial growth; the costs of our commercialization plans and development programs, and the financial impact or revenues from any commercialization we undertake; our ability to obtain necessary regulatory approvals for our product candidates and, if and when approved, market acceptance of our products; the risks associated with clinical trials and their outcomes, including

risks of unsuccessful enrollment and negative or inconsistent results; our dependence on third-party collaborators, clinical research organizations, manufacturers, suppliers and distributors; the impact of competitive products and therapies; our ability to generate or obtain the necessary capital to fund our operations; our ability to grow, equip and train our specialized sales forces; our ability to manage the growth and complexity of our organization; our ability to maintain, protect and enhance our intellectual property; and our ability to continue to stay in compliance with applicable laws and regulations. Given the risks and uncertainties, you should not place undue reliance on these forward-looking statements. For a discussion of these and other risks, uncertainties and other factors that may cause our actual results, performance or achievements to differ, please refer to our quarterly report on Form 10-Q for the period ended June 30, 2026, filed on August 5, 2026, as well as our subsequent filings with the Securities and Exchange Commission from time to time. The forward-looking statements contained herein are made as of the date hereof, and we undertake no obligation to update them after this date, except as required by law. ACADIA PHARMACEUTICALS INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (Unaudited)

ACADIA PHARMACEUTICALS INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands)

Full text with the tables
                                                                    Exhibit 99.1
      Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results       
                                                                                
 - Third quarter GAAP total revenues of $342 million, up 22% year-over-year as  
                  compared to non-GAAP adjusted total revenues                  
                                                                                
  - Third quarter DAYBUE®GAAP net sales of $140 million, up 39% year-over-year  
                     driven by strong uptake of DAYBUE STIX                     
                                                                                
 - Third quarter NUPLAZID®GAAP net sales of $202 million, up 12% year-over-year 
                          on a non-GAAP adjusted basis                          
                                                                                
 - Raises 2026 DAYBUE net sales guidance to $505–$520 million; narrows NUPLAZID 
                         range and total revenue range                          
                                                                                
- Additional data from Phase 3-enabling RADIANT Phase 2 Study to be presented at
      the Clinical Trials on Alzheimer’s Disease conference on November 17      
SAN DIEGO, CA, November 4, 2026– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD),    
today announced its financial results for the third quarter ended September 30, 
2026.                                                                           
                                                                                
“Acadia delivered a strong third quarter, with total revenues of $342 million   
and continued commercial momentum across DAYBUE and NUPLAZID,” said Catherine   
Owen Adams, Chief Executive Officer of Acadia. “In the U.S., DAYBUE delivered   
another strong quarter, supported by meaningful uptake of DAYBUE STIX. In       
Europe, we are excited to build momentum following our recent launch of DAYBU in
Germany. NUPLAZID also performed well, driven by underlying demand and the      
continued expansion of our commercial reach. Together, these growing franchises 
provide the commercial and financial foundation to advance clinical programs    
with the potential to become Acadia’s next meaningful growth opportunities. In  
Alzheimer’s disease psychosis, we are continuing Phase 3 development of         
remlifanserin based on Phase 2 results. As we look ahead to 2027, we anticipate 
two Phase 2 readouts: ACP-211 in major depressive disorder, and remlifanserin in
Lewy body dementia psychosis, for which we are providing timing guidance for the
first time. We look forward to sharing these updates as we continue to advance  
the next wave of our pipeline.”                                                 
                                                                                
Company Updates                                                                 
                                                                                
Announced Phase 3-enabling topline results from the Phase 2 RADIANT study of    
remlifanserin in Alzheimer’s disease psychosis, with consistent efficacy trends 
at the 60 mg dose across all four psychosis scales that were assessed for the   
full study population and a favorable safety and tolerability profile supporting
continued and optimized Phase 3 development. Additional data will be presented  
at the Clinical Trials on Alzheimer’s Disease conference on November 17, 2026,  
in Boston.                                                                      
                                                                                
Two Phase 2 readouts anticipated in 2027: ACP-211 in major depressive disorder  
(MDD) in the second half and, for the first time, guidance for remlifanserin in 
Lewy body dementia Psychosis (LBDP) in the fourth quarter.                      
                                                                                
Received FDA Fast Track designation for remlifanserin for the treatment of Lewy 
body dementia psychosis, recognizing the significant unmet need for new         
treatment options.                                                              
                                                                                
Received allowance of a new U.S. patent covering weight-banded dosing of        
trofinetide, extending U.S. patent protections for DAYBUE and DAYBUE STIX by    
nearly five years, through March 2041.                                          
                                                                                
Received European Commission approval for DAYBU ® (trofinetide) as the first and
only treatment for the neurobehavioral symptoms of Rett syndrome in adults and  
pediatric patients aged five years and older in the European Union in August    
2026 and launched DAYBU in Germany in early October 2026 with patients already  
receiving commercial product.                                                   
                                                                                
Completed the Phase 3 study of trofinetide in Rett syndrome in Japan, with      
results consistent with the LAVENDER Phase 3 study and supportive of a planned  
regulatory filing; Acadia continues to pursue a distribution partner in         
preparation for regulatory filing in 2027 and a potential launch in 2028,       
subject to regulatory approval.                                                 
                                                                                
Financial Results                                                               
                                                                                
Revenues                                                                        
                                                                                
GAAP total revenues, consisting of net product sales from NUPLAZID and DAYBUE,  
were $342 million in the third quarter of 2026, up 23% as compared to GAAP total
revenues of $279 million in the third quarter of 2025, and up 22% as compared to
non-GAAP adjusted total revenues of $281 million in the third quarter of 2025.  
                                                                                
GAAP net product sales of NUPLAZID were $202 million in the third quarter of    
2026, up 14% as compared to GAAP net product sales of $178 million in the third 
quarter of 2025, and up 12% as compared to non-GAAP adjusted net product sales  
of $180 million in the third quarter of 2025.                                   
                                                                                
Net product sales of DAYBUE were $140 million in the third quarter of 2026, an  
increase of 39% as compared to $101 million in the third quarter of 2025.       
                                                                                
A reconciliation of NUPLAZID non-GAAP adjusted net product sales and non-GAAP   
adjusted total revenues is provided in Table 1. A description of these          
adjustments is included under ‘Non-GAAP Financial Measures.’                    
                                                                                
Research and Development                                                        
                                                                                
Research and development expenses in the third quarter of 2026 were $76 million,
as compared to $88 million for the same period of 2025.                         
                                                                                
Selling, General and Administrative                                             
                                                                                
Selling, general and administrative expenses in the third quarter of 2026 were  
$159 million, as compared to $133 million for the same period of 2025.          
                                                                                
Net Income                                                                      
                                                                                
For the third quarter of 2026, Acadia reported net income of $54 million, or    
$0.31 per diluted share, as compared to net income of $72 million, or $0.42 per 
diluted share, for the same period of 2025.                                     
                                                                                
Cash and Investments                                                            
                                                                                
At September 30, 2026, Acadia’s cash, cash equivalents, and investment          
securities totaled $976 million, as compared to $820 million at December 31,    
2025.                                                                           
                                                                                
Full Year 2026 Financial Guidance (GAAP):                                       
                                                                                
Acadia is updating its 2026 guidance:                                           
                                                                                
Total revenues revised to a range of $1.265 to $1.295 billion, compared with a  
previous range of $1.24 to $1.30 billion.                                       
                                                                                
NUPLAZID net product sales narrowed to a range of $760 to $775 million, compared
with the previous guidance range of $760 to $790 million.                       
                                                                                
DAYBUE (including all forms of trofinetide) global net product sales in the     
range of $505 to $520 million, up from the previous range of $480 to $510       
million.                                                                        
                                                                                
R&D expense in the range of $325 to $340 million, down from the previous range  
of $355 to $380 million.                                                        
                                                                                
SG&A expense in the range of $665 to $685 million, compared with the previous   
guidance range of $660 to $700 million.                                         
                                                                                
Conference Call and Webcast Information                                         
                                                                                
Acadia will host a conference call to discuss the third quarter 2026 results    
today, Wednesday, November 4, 2026 at 1:30 p.m. PT/4:30 p.m. ET. The conference 
call may be accessed by registering for the callhere. Once registered,          
participants will receive an email with the dial-in number and unique PIN to use
for accessing the call.                                                         
                                                                                
About NUPLAZID®(pimavanserin)                                                   
                                                                                
Pimavanserin is a selective serotonin inverse agonist and antagonist            
preferentially targeting 5-HT2A receptors. These receptors are thought to play  
an important role in neuropsychiatric disorders. In vitro, pimavanserin         
demonstrated no appreciable binding affinity for dopamine (including D2),       
histamine, muscarinic, or adrenergic receptors. Pimavanserin was approved for   
the treatment of hallucinations and delusions associated with Parkinson’s       
disease psychosis by the U.S. Food and Drug Administration in April 2016 under  
the trade name NUPLAZID.                                                        
                                                                                
About DAYBUE®(trofinetide)                                                      
                                                                                
Trofinetide is a synthetic version of a naturally occurring molecule known as   
the tripeptide glycine-proline-glutamate (GPE). The mechanism by which          
trofinetide exerts therapeutic effects in patients with Rett syndrome is        
unknown. Trofinetide was first approved for the treatment of Rett syndrome in   
adults and pediatric patients 2 years of age and older by the U.S. Food and Drug
Administration in March 2023 under the trade name DAYBUE. Trofinetide is        
approved for use under the name DAYBUE®and DAYBUE®STIX in the United States and 
under the name DAYBUE®in Canada and DAYBU®in the European Union. References to  
DAYBUE net product sales include global net product sales of all commercially   
available forms of trofinetide, including those referenced above.               
                                                                                
About Acadia Pharmaceuticals                                                    
                                                                                
Acadia is committed to turning scientific promise into meaningful innovation    
that makes the difference for underserved neurological and rare disease         
communities around the world. Our commercial portfolio includes the first and   
only FDA-approved treatments for Parkinson’s disease psychosis and Rett         
syndrome. We are developing the next wave of therapeutic advancements with a    
robust and diverse                                                              
                                                                                
pipeline that includes mid- to late-stage programs in Alzheimer’s disease       
psychosis and Lewy body dementia psychosis, along with earlier-stage programs   
that address other underserved patient needs. At Acadia, we’re here to be their 
difference. For more information, visit us at acadia.com and follow us          
onLinkedInandX.                                                                 
                                                                                
Non-GAAP Financial Measures                                                     
                                                                                
This press release contains the following financial measures that do not comply 
with U.S. generally accepted accounting principles (GAAP): non-GAAP adjusted net
product sales for NUPLAZID for the third quarter of 2025 and non-GAAP adjusted  
total revenues for the third quarter of 2025. In preparing these non-GAAP       
financial results, the Company includes adjustments made to reflect the impact  
of a change in estimate related to NUPLAZID IRA rebate accruals. Please refer to
our press release dated February 25, 2026, for additional details. These non-   
GAAP financial measures complement GAAP results and are used by management to   
analyze financial performance and evaluate period-to-period changes. Management 
believes these non-GAAP financial measures are useful to investors and other    
users of the Company’s financial statements to facilitate period-to-period      
comparability. These non-GAAP financial measures are not meant to be considered 
as a substitute for comparable GAAP measures; should be read in conjunction with
the Company’s consolidated financial statements prepared in accordance with     
GAAP; have no standardized meaning prescribed by GAAP; and are unlikely to be   
comparable with non-GAAP disclosures released by other companies.               
                                                                                
Forward-Looking Statements                                                      
                                                                                
This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking statements    
include all statements other than statements of historical fact and can be      
identified by terms such as “may,” “will,” “should,” “could,” “would,”          
“expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,”         
“predicts,” “potential,” “guidance,” “continue” and similar expressions         
(including the negative thereof) intended to identify forward-looking           
statements. Forward-looking statements contained in this press release, include,
but are not limited to, statements about: (i) our business strategy, objectives 
and opportunities, including support for and innovations in our pipeline assets 
and business development opportunities, sales growth for DAYBUE [products] and  
uptake of DAYBUE STIX and DAYBU in the European Union and the potential for     
enhanced shareholder value; (ii) the momentum and expectations for NUPLAZID’s   
commercial reach, (iii) the strength and loss of exclusivity date of our        
trofinetide patent protection; (iv) plans for, including timing, development and
progress of commercialization, clinical and regulatory milestones for, our      
products and our product candidates, including trofinetide in Japan,            
remlifanserin in ADP and LBDP, and ACP-211 in MDD; (v) benefits to be derived   
from and efficacy of our products, including the potential advantages of our    
products; (vi) our expectations to advance our clinical programs and their      
potential to become meaningful growth opportunities, including our belief that  
the results from the Phase 2 RADIANT study will enable the Phase 3 study of     
remlifanserin in Alzheimer’s disease psychosis; (vii) our plans to pursue       
distribution partnerships for trofinetide in Rett syndrome; and (viii) our      
estimates regarding our future financial performance, profitability, capital    
requirements or expenses, including our full year 2026 financial guidance,      
revenue opportunities and anticipated net product sales by the end of 2028.     
Forward-looking statements are subject to known and unknown risks,              
uncertainties, assumptions and other factors that may cause our actual results, 
performance or achievements to differ materially and adversely from those       
anticipated or implied by our forward-looking statements. Such risks,           
uncertainties and other factors include, but are not limited to: our dependency 
on the continued successful commercialization of our products and our ability to
maintain or increase sales of our products; the success of our plans to continue
commercial growth; the costs of our commercialization plans and development     
programs, and the financial impact or revenues from any commercialization we    
undertake; our ability to obtain necessary regulatory approvals for our product 
candidates and, if and when approved, market acceptance of our products; the    
risks associated with clinical trials and their outcomes, including             
                                                                                
risks of unsuccessful enrollment and negative or inconsistent results; our      
dependence on third-party collaborators, clinical research organizations,       
manufacturers, suppliers and distributors; the impact of competitive products   
and therapies; our ability to generate or obtain the necessary capital to fund  
our operations; our ability to grow, equip and train our specialized sales      
forces; our ability to manage the growth and complexity of our organization; our
ability to maintain, protect and enhance our intellectual property; and our     
ability to continue to stay in compliance with applicable laws and regulations. 
Given the risks and uncertainties, you should not place undue reliance on these 
forward-looking statements. For a discussion of these and other risks,          
uncertainties and other factors that may cause our actual results, performance  
or achievements to differ, please refer to our quarterly report on Form 10-Q for
the period ended June 30, 2026, filed on August 5, 2026, as well as our         
subsequent filings with the Securities and Exchange Commission from time to     
time. The forward-looking statements contained herein are made as of the date   
hereof, and we undertake no obligation to update them after this date, except as
required by law.                                                                
ACADIA PHARMACEUTICALS INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in
thousands, except per share amounts) (Unaudited)
                                                                                
           Three                              Nine                              
           Mont…                              Months                            
           Ended                              Ended                             
           Sept…                              Septe…                            
           30,                                30,                               
  Reve…    2026             2025              2026             2025             
 ────────────────────────────────────────────────────────────────────────────── 
  Prod…                                                                         
  sale…    $      342,2…    $     278,…       $       918,…    $     787,5…     
  net                                                                           
  Total           342,2…          278,…               918,…          787,5…     
  reve…                                                                         
  Oper…                                                                         
  expe…                                                                         
  Cost                                                                          
  of                                                                            
  prod…           35,090          21,6…               88,1…          62,773     
  sales                                                                         
  (1)(…                                                                         
  Rese…                                                                         
  and             76,282          87,8…               234,…          244,0…     
  deve…                                                                         
  (2)                                                                           
  Sell…                                                                         
  gene…                                                                         
  and             159,2…          133,…               490,…          393,2…     
  admi…                                                                         
  (2)                                                                           
  Total                                                                         
  oper…           270,5…          242,…               813,…          700,0…     
  expe…                                                                         
  (Los…                                                                         
  inco…           71,718          35,7…               104,…          87,420     
  from                                                                          
  oper…                                                                         
  Inte…                                                                         
  inco…            8,421          8,246               24,4…          23,390     
  net                                                                           
  Other              300            593               1,489           1,775     
  inco…                                                                         
  Inco…                                                                         
  befo…           80,439          44,5…               130,…          112,5…     
  inco…                                                                         
  taxes                                                                         
  Inco…                                                                         
  tax             26,915          (27,…  )            42,2…          (4,847  )  
  expe…                                                                         
  (ben…                                                                         
  Net      $      53,524    $     71,7…       $       88,6…    $     117,4…     
  inco…                                                                         
  Earn…                                                                         
  per                                                                           
  shar…                                                                         
  Basic    $        0.31    $      0.43       $        0.52    $       0.70     
  Dilu…    $        0.31    $      0.42       $        0.51    $       0.69     
  Weig…                                                                         
  aver…                                                                         
  comm…                                                                         
  shar…                                                                         
  outs…                                                                         
  Basic           172,5…          168,…               171,…          167,8…     
  Dilu…           175,4…          170,…               173,…          169,1…     
  (1)                                                                           
  Incl…                                                                         
  lice…                                                                         
  fees                                                                          
  and                                                                           
  roya…                                                                         
  (2)                                                                           
  Incl…                                                                         
  the                                                                           
  foll…                                                                         
  stoc…                                                                         
  comp…                                                                         
  expe…                                                                         
  Cost                                                                          
  of       $         451    $       372       $       1,290    $        724     
  prod…                                                                         
  sales                                                                         
  Rese…                                                                         
  and      $       4,674    $     4,312       $       13,5…    $     12,222     
  deve…                                                                         
  Sell…                                                                         
  gene…    $      12,325    $     8,496       $       34,2…    $     25,954     
  and                                                                           
  admi…                                                                         
                                                                                
ACADIA PHARMACEUTICALS INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands)
(Unaudited)
                                                                                
                                              September 30,       December 31,  
                                                       2026               2025  
 ────────────────────────────────────────────────────────────────────────────── 
                                  -unaudited                                    
  Assets                                                                        
  Cash, cash equivalents and                                                    
  investment                      $                 976,446    $       819,686  
  securities                                                                    
  Accounts receivable, net                          161,017            121,457  
  Interest and other                                 17,298             26,774  
  receivables                                                                   
  Inventory                                          40,360             34,670  
  Prepaid expenses and other                                                    
  current                                            73,305             59,526  
  assets                                                                        
  Total current assets                            1,268,426          1,062,113  
  Property and equipment, net                        18,403              7,511  
  Operating lease right-of-use                       67,468             47,354  
  assets                                                                        
  Intangible assets, net                            135,483            108,893  
  Restricted cash                                     7,846              7,845  
  Long-term inventory                                66,484             76,704  
  Deferred tax assets                               226,719            249,879  
  Other assets                                        3,322              3,896  
  Total assets                    $               1,794,151    $     1,564,195  
  Liabilities and                                                               
  stockholders’ equity                                                          
  Accounts payable                $                  16,330    $        10,903  
  Accrued liabilities                               315,887            266,211  
  Total current liabilities                         332,217            277,114  
  Operating lease liabilities                        57,322             40,554  
  Other long-term liabilities                        17,123             19,137  
  Total liabilities                                 406,662            336,805  
  Total stockholders’ equity                      1,387,489          1,227,390  
  Total liabilities and                                                         
  stockholders’                   $               1,794,151    $     1,564,195  
  equity                                                                        
                                                                                
Table 1. ACADIA PHARMACEUTICALS INC. NON-GAAP RECONCILIATION (in millions)
(Unaudited)
                                                                    
                                               3Q25           3Q26  
 ────────────────────────────────────────────────────────────────── 
  GAAP NUPLAZID Net Sales                  $  177.5       $  202.2  
  Change in estimate recorded in period    $    4.9       $      —  
  Allocation of 2025 Amount                $   (2.6  )    $      —  
  Non-GAAP Adjusted NUPLAZID Net Sales     $  179.8       $  202.2  
  DAYBUE products Net Sales                $  101.1       $  140.1  
  Non-GAAP Adjusted Total Revenues         $  280.9       $  342.3  
                                                                    
Investor Contact:                                                               
                                                                                
Acadia Pharmaceuticals Inc.                                                     
                                                                                
Al Kildani                                                                      
                                                                                
(858) 261-2872                                                                  
                                                                                
[email protected]                                                             
                                                                                
Acadia Pharmaceuticals Inc.                                                     
                                                                                
Jessica Tieszen                                                                 
                                                                                
(858) 261-2950                                                                  
                                                                                
[email protected]                                                             
                                                                                
Media Contact:                                                                  
                                                                                
Acadia Pharmaceuticals Inc.                                                     
                                                                                
Deb Kazenelson(818) 395-3043                                                    
                                                                                
[email protected]                                                          

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ACAD/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.